These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 15805284

  • 1. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.
    Kambara H, Okano H, Chiocca EA, Saeki Y.
    Cancer Res; 2005 Apr 01; 65(7):2832-9. PubMed ID: 15805284
    [Abstract] [Full Text] [Related]

  • 2. Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of malignant glioma.
    Kanai R, Tomita H, Hirose Y, Ohba S, Goldman S, Okano H, Kawase T, Yazaki T.
    Hum Gene Ther; 2007 Jan 01; 18(1):63-73. PubMed ID: 17238803
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors.
    Andreansky S, Soroceanu L, Flotte ER, Chou J, Markert JM, Gillespie GY, Roizman B, Whitley RJ.
    Cancer Res; 1997 Apr 15; 57(8):1502-9. PubMed ID: 9108452
    [Abstract] [Full Text] [Related]

  • 4. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.
    Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, McGrath Y, Thomas SK, Thornton M, Bullock P, Love CA, Coffin RS.
    Gene Ther; 2003 Feb 15; 10(4):292-303. PubMed ID: 12595888
    [Abstract] [Full Text] [Related]

  • 5. Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of gamma34.5-mediated virulence.
    Kanai R, Tomita H, Shinoda A, Takahashi M, Goldman S, Okano H, Kawase T, Yazaki T.
    Gene Ther; 2006 Jan 15; 13(2):106-16. PubMed ID: 16163378
    [Abstract] [Full Text] [Related]

  • 6. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
    Coukos G, Makrigiannakis A, Montas S, Kaiser LR, Toyozumi T, Benjamin I, Albelda SM, Rubin SC, Molnar-Kimber KL.
    Cancer Gene Ther; 2000 Feb 15; 7(2):275-83. PubMed ID: 10770637
    [Abstract] [Full Text] [Related]

  • 7. A herpes simplex virus type 1 mutant deleted for gamma34.5 and LAT kills glioma cells in vitro and is inhibited for in vivo reactivation.
    Samoto K, Perng GC, Ehtesham M, Liu Y, Wechsler SL, Nesburn AB, Black KL, Yu JS.
    Cancer Gene Ther; 2001 Apr 15; 8(4):269-77. PubMed ID: 11393279
    [Abstract] [Full Text] [Related]

  • 8. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
    Aghi M, Rabkin SD, Martuza RL.
    Cancer Res; 2007 Jan 15; 67(2):440-4. PubMed ID: 17234749
    [Abstract] [Full Text] [Related]

  • 9. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer.
    Coukos G, Makrigiannakis A, Kang EH, Rubin SC, Albelda SM, Molnar-Kimber KL.
    Clin Cancer Res; 2000 Aug 15; 6(8):3342-53. PubMed ID: 10955822
    [Abstract] [Full Text] [Related]

  • 10. Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.
    Kambara H, Saeki Y, Chiocca EA.
    Cancer Res; 2005 Dec 15; 65(24):11255-8. PubMed ID: 16357128
    [Abstract] [Full Text] [Related]

  • 11. Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy.
    Han ZQ, Assenberg M, Liu BL, Wang YB, Simpson G, Thomas S, Coffin RS.
    J Gene Med; 2007 Feb 15; 9(2):99-106. PubMed ID: 17256802
    [Abstract] [Full Text] [Related]

  • 12. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.
    Lun X, Senger DL, Alain T, Oprea A, Parato K, Stojdl D, Lichty B, Power A, Johnston RN, Hamilton M, Parney I, Bell JC, Forsyth PA.
    J Natl Cancer Inst; 2006 Nov 01; 98(21):1546-57. PubMed ID: 17077357
    [Abstract] [Full Text] [Related]

  • 13. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
    Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Canron X, Bikfalvi A, Martuza RL, Kurtz A, Rabkin SD.
    Clin Cancer Res; 2006 Nov 15; 12(22):6791-9. PubMed ID: 17121900
    [Abstract] [Full Text] [Related]

  • 14. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
    Shah AC, Parker JN, Gillespie GY, Lakeman FD, Meleth S, Markert JM, Cassady KA.
    Gene Ther; 2007 Jul 15; 14(13):1045-54. PubMed ID: 17429445
    [Abstract] [Full Text] [Related]

  • 15. Antitumor effect of vaccinia virus in glioma model.
    Timiryasova TM, Li J, Chen B, Chong D, Langridge WH, Gridley DS, Fodor I.
    Oncol Res; 1999 Jul 15; 11(3):133-44. PubMed ID: 10527073
    [Abstract] [Full Text] [Related]

  • 16. Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells.
    Taneja S, MacGregor J, Markus S, Ha S, Mohr I.
    Proc Natl Acad Sci U S A; 2001 Jul 17; 98(15):8804-8. PubMed ID: 11438715
    [Abstract] [Full Text] [Related]

  • 17. Gene delivery to the central and peripheral nervous systems of mice using HSV1 ICP34.5 deletion mutant vectors.
    Coffin RS, MacLean AR, Latchman DS, Brown SM.
    Gene Ther; 1996 Oct 17; 3(10):886-91. PubMed ID: 8908502
    [Abstract] [Full Text] [Related]

  • 18. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas.
    Herrlinger U, Woiciechowski C, Sena-Esteves M, Aboody KS, Jacobs AH, Rainov NG, Snyder EY, Breakefield XO.
    Mol Ther; 2000 Apr 17; 1(4):347-57. PubMed ID: 10933953
    [Abstract] [Full Text] [Related]

  • 19. Sox10 has a broad expression pattern in gliomas and enhances platelet-derived growth factor-B--induced gliomagenesis.
    Ferletta M, Uhrbom L, Olofsson T, Pontén F, Westermark B.
    Mol Cancer Res; 2007 Sep 17; 5(9):891-7. PubMed ID: 17855658
    [Abstract] [Full Text] [Related]

  • 20. Preferential expression of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival.
    Bian XW, Yang SX, Chen JH, Ping YF, Zhou XD, Wang QL, Jiang XF, Gong W, Xiao HL, Du LL, Chen ZQ, Zhao W, Shi JQ, Wang JM.
    Neurosurgery; 2007 Sep 17; 61(3):570-8; discussion 578-9. PubMed ID: 17881971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.